BioRestorative Therapies (BRTX) Profit After Tax (2010 - 2025)

BioRestorative Therapies (BRTX) has 16 years of Profit After Tax data on file, last reported at -$3.2 million in Q4 2025.

• Quarterly Profit After Tax fell 95.58% year-over-year to -$3.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$14.2 million (down 58.52% YoY) and the FY2025 annual result came in at -$14.2 million, down 58.14% from the prior year.
• Profit After Tax eased to -$3.2 million in Q4 2025, from -$3.0 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of $4.8 million in Q3 2023 to a low of -$20.4 million in Q4 2021.
• A 5-year average of -$4.6 million and a median of -$3.6 million in 2024 frame the typical range for Profit After Tax.
• Annual changes were most pronounced in 2021 — Profit After Tax plunged 400.35% — and 2023, when it surged 187.55%.
• Tracing BRTX's Profit After Tax over 5 years: stood at -$20.4 million in 2021, then surged by 86.92% to -$2.7 million in 2022, then grew by 13.66% to -$2.3 million in 2023, then gained by 28.99% to -$1.6 million in 2024, then sank by 95.58% to -$3.2 million in 2025.
• The last three Profit After Tax figures came in at -$3.2 million (Q4 2025), -$3.0 million (Q3 2025), and -$2.7 million (Q2 2025), per Business Quant data.